News

My Green Lab announced a collaboration with AstraZeneca to implement a global-scale green labs program across their research sites as part of their commitment to sustainability,…
Read More...

Astellas Pharma Inc., through its wholly-owned subsidiary Universal Cells, Inc, and Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that they have…
Read More...

MorphoSys AG and Incyte Corporation announced that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys' proprietary…
Read More...

Charles River announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Together, Charles River and Takeda will launch multiple integrated programs…
Read More...

BioMotiv, a mission-driven pharma company part of The Harrington Project for discovery and development, and Atomwise, the leader in using artificial intelligence (AI) for small molecule…
Read More...

Coherus BioSciences, Inc. announced the Company has entered into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd. to commercialize Innovent’s biosimilar candidate to…
Read More...

Alnylam Pharmaceuticals announced that the Company has initiated a rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lumasiran, an…
Read More...

Zymeworks Inc. announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific…
Read More...

eFFECTOR Therapeutics and Pfizer Inc. announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E…
Read More...

Eli Lilly and Company and Dermira, Inc. announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction.…
Read More...

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, reported that the previously…
Read More...

Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis, a clinical-stage biopharmaceutical company focused on…
Read More...

PPD, Inc. (PPD) has expanded its operations and leadership team in China to provide enhanced clinical development, laboratory, regulatory, site conduct, patient access and post-approval…
Read More...

Almirall, S.A. and WuXi Biologics have announced the signing of an agreement. Through this collaboration Almirall embarks on its strategy to develop highly innovative biologic products…
Read More...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with…
Read More...

Galen announced the completion of a multi-million pound acquisition and takeover of boutique healthcare company, POA Pharma. The move enables Galen to significantly expand its global…
Read More...

Almirall, S.A. (ALM) has announced  the execution of an option agreement to acquire Bioniz Therapeutics, Inc. a clinical stage biopharmaceutical company based in Irvine, California,…
Read More...

ProBioGen AG has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX technology to boost the antibody’s ADCC anti-tumor activity. The…
Read More...

Incyte announced the validation of the Company’s Marketing Authorization Application (MAA) for pemigatinib for the treatment of adults with locally advanced or metastatic…
Read More...

Evotec SE announced that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines.…
Read More...